Table 2.
Ec-SOD ≤ 83 U/L (n = 59) | Ec-SOD > 83 U/L (n = 74) | P-valuea | |
---|---|---|---|
Age, years | 31 (25, 48) | 39 (29, 52) | 0.022 |
Female gender, n (%) | 45 (76) | 49 (66) | <0.001 |
BMI, kg/m2 | 22 (19, 23) | 22 (21, 24) | 0.500 |
BMPR2 mutation | 17 (29) | 11 (15) | 0.521 |
WHO FC, n (%) | <0.001 | ||
Class II | 14 (24) | 31 (42) | |
Class III | 35 (59) | 36 (49) | |
Class IV | 10 (17) | 7 (9) | |
Onset to diagnosis, months | 18 (6, 33) | 34 (7, 60) | 0.033 |
6MWD, metersb | 360 (276, 415) | 390 (329, 452) | 0.008 |
BNP, pg/ml | 387 (158, 529) | 319 (147, 488) | 0.857 |
Cu/Zn-SOD, U/ml | 146 (110, 213) | 148 (120, 213) | 0.911 |
Mn-SOD, U/ml | 46 (34, 90) | 39 (29, 52) | 0.082 |
Hemodynamic variables | |||
HR, bpm | 82 (73, 94) | 86 (76, 97) | 0.409 |
mRAP, mmHg | 8 (5, 13) | 7 (5, 11) | 0.631 |
mPAP, mmHg | 63 (54, 77) | 59 (50, 67) | 0.048 |
PAWP, mmHg | 9 (6, 11) | 9 (7, 12) | 0.453 |
CO, L/min | 3.5 (3.0, 4.5) | 3.6 (2.9, 5.0) | 0.410 |
CI, L/min/m2 | 2.3 (1.8, 2.8) | 2.2 (1.8, 2.8) | 0.792 |
PVR, Wood units | 16 (12, 22) | 14 (9, 17) | 0.040 |
SVO2, % | 58 (53, 62) | 61 (54, 68) | 0.192 |
Values are expressed as medians (interquartile range), except for female gender and WHO functional class, which are numbers of patients (%).
Comparison between groups with Ec-SOD ≤ 83 U/L and Ec-SOD > 83 U/L.
6MWD could be successfully measured in 124 patients.
BMI, body mass index; BMPR 2, bone morphogenetic protein receptor type 2; BNP, brain natriuretic peptide; CI, cardiac index; CO, cardiac output; Cu/Zn-SOD, copper–zinc superoxide dismutase; Ec-SOD, extracellular form of Cu/Zn superoxide dismutase; HR, heart rate; Mn-SOD, manganese superoxide dismutase; mPAP, mean pulmonary arterial pressure; mRAP, mean right atrial pressure; 6MWD, 6-min walking distance; PAWP, pulmonary artery wedge pressure; PVR, pulmonary vascular resistance; SvO2, mixed venous oxygen saturation; WHO FC, World Health Organization functional class.